News and Updates

iVeena announces the appointment of Dr. Jerry Hu, MD to the iVeena Scientific Advisory Board. 

17 September 2019

Dr. Hu is a leading private practitioner with a keen interest in academic and research endeavors. He is a partner and owner of Texas Eye and Laser Center, an internationally recognized center of excellence, and a co-founder of Texas Eye and Laser Center.

Dr. Jerry Hu completed a fellowship in Cornea and Refractive Surgery with the world-renowned Jules Stein Eye Institute at UCLA.  Following his graduation from Davidson College in North Carolina, Dr. Hu attended Duke University School of Medicine where he also completed his residency in ophthalmology. 

Dr. Hu is a leading private practitioner with a keen interest in academic and research endeavors. He is a partner and owner of Texas Eye and Laser Center, an internationally recognized center of excellence, and a co-founder of Texas Eye and Laser Center. Dr. Hu specializes in Refractive Surgery, Cataract Surgery, as well as Cornea and Anterior Segment Diseases. He pioneers a wide range of cutting-edge ophthalmic surgeries including SMILE, blade-free LASIK, laser-assisted cataract surgery, intraoperative wavefront aberrometry, MIGS procedures, Intacs, cornea collagen crosslinking, and laser-enabled minimally invasive corneal transplantations, etc.

One of Dr. Hu’s main professional objectives is his contribution to the advancements of medical and surgical technologies in ophthalmology. He heads a robust research program as a principal investigator of numerous FDA clinical trials investigating the next generation intraocular lens implants, surgical devices, diagnostic equipment and pharmaceutical agents. A fervent teacher and educator, Dr. Hu is a frequent lecturer and speaker at many national and regional conferences.

Dr. Hu and his dedicated associates also offer a complete range of eye care services including treatment of glaucoma, macular degeneration, diabetic retinopathy and dry eye syndrome.

iVeena announces the appointment of Dr. Vance Thompson, MD, to the iVeena Scientific Advisory Board.

17 September 2019

Dr. Thompson is an internationally recognized specialist in Laser Vision Correction and Advanced Cataract Surgery.

Vance Thompson, MD is an internationally recognized specialist in Laser Vision Correction and Advanced Cataract Surgery. He is the Founder of Vance Thompson Vision Sioux Falls, SD  and the Director of Refractive Surgery he also serves as a Professor of Ophthalmology at the Sanford USD School of Medicine. As a leading international researcher he has played a key role in the development of the most advanced technologies and techniques for both laser and implant vision correction. He has served as the medical monitor lead or principal investigator in over 72 FDA monitored clinical trials studying laser and implant surgery. In addition, Dr. Thompson has published numerous papers and book chapters and is co-author of the textbook Refractive Surgery. He has lectured and taught advanced laser and implant surgery to thousands of surgeons all around the world.

A Gregory, South Dakota native, Dr. Thompson received his BS in Chemistry and his MD degree from the University of South Dakota. After completing his ophthalmology residency at the University of Missouri/Columbia, he was accepted and completed a fellowship in Refractive and Cataract Surgery with Dan Durrie, MD and John Hunkeler, MD at Hunkeler Eye Centers in Kansas City.

Dr. Thompson and his wife Jana reside in Sioux Falls, South Dakota. They have 3 children, Blake (and his wife Kayla), Joel, Lauren and two grandsons. His main interests include his family, cooking, and spending time in the outdoors.

iVeena announces the appointment of Robert Dempsey, Group Vice President and Head of the Global Ophthalmology Franchise at Takeda (formerly Shire) to the iVeena Board of Directors

05 August 2019

iVeena announces the appointment of Robert Dempsey, Group Vice President and Head of the Global Ophthalmology Franchise at Takeda (formerly Shire) to the iVeena Board of Directors.

“Mr. Dempsey will add considerable ophthalmology sector expertise to the iVeena team at a critical time in the development of the company as it progresses through its late stage clinical programs for post cataract surgery inflammation and pain, a non-invasive keratoconus orphan drug and a new treatment for progressive myopia” said Jerry Simmons, iVeena CEO.

iVeena awarded top prize for most promising new products in the field of ophthalmology at the American Society of Cataract and Refractive Surgeons annual conference.

20 May 2019

iVeena receives top award at the American Society of Cataract and Refractive Surgeons

At the May 4, 2019 American Society of Cataract and Refractive Surgeons, Dr. Ambati (iVeena President and Founder) presented the iVeena products in development at the inaugural Winning Pitch Challenge. The Challenge was chaired by prominent Key Opinion leaders and institutional investors. The esteemed panel of KOL's and industry leading judges voted iVeena's keratoeonus and progressive myopia projects the best out of 60 submissions and awarded Dr. Ambati the top prize.  "In short, the Academy award suggests that these two iVeena projects are two of the most promising technologies in the field of ophthalmology today said Jerry Simmons, CEO of iVeena Delivery Systems.”

iVeena announces the commencement of a 36 patient Phase 1/2a pilot clinical study for the treatment of keratoconus.

04 February 2019

iVeena announces the commencement of a 36 patient Phase I/2a pilot clinical study for the treatment of Keratoconus (IVMED-80). The Company has Orphan Drug Designation for this product.

Mountain Pacific Venture Fund invests in ocular drug development company iVeena

04 February 2019

iVeena announces the first close for its $2.75M Series B financing by Mountain Pacific Venture Fund, a health care/biotech focused venture fund.

iVeena receives Notice of Allowance from the US Patent Office for patent protecting cataract implants (IVMED 10&20).

12 December 2017

Salt Lake City, Utah,--(BUSINESS WIRE)--iVeena Delivery Systems (iVeena), a biopharmaceutical company that develops innovative ophthalmology products, today announced that the United States Patent and Trademark Office (USPTO) communicated a notice of allowance for a patent assigned to the University of Utah and licensed to iVeena Delivery Systems Inc.

iVeena Receives FDA Orphan Drug Designation for IVMED-80 for the Treatment of Keratoconus

30 October 2017

iVeena announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IVMED-80, for the treatment of keratoconus. Keratoconus is a degenerative disorder causing a cornea to become conical in shape that can seriously distort vision. This may lead to a corneal transplant. IVMED-80 is the first eye-drop, non-surgical, non-laser treatment for medical crosslinking of the cornea.